Jasper Therapeutics Inc

Jasper Therapeutics has a highly liquid capital structure, with $118.48 million in cash and equivalents and no long-term debt, resulting in a debt-to-equity ratio of 0.0. The company's current ratio of 13.49 indicates strong short-term liquidity, with total assets of $125.96 million and total liabilities of $12.73 million. The price-to-book ratio of 0.24 and price-to-tangible-book ratio of 0.24 suggest the company is trading at a significant discount to its book value. The company is currently unprofitable, with a net loss of $13.73 million and an operating loss of $15.07 million in the latest period. Return on equity (ROE) and return on assets (ROA) are negative at -12.12% and -10.90%, respectively, indicating poor capital efficiency and asset utilization. The EV/EBITDA ratio of 6.08 is not meaningful due to the company's negative EBITDA, but it suggests a low valuation multiple in the context of its current financial performance. Jasper Therapeutics does not disclose segment or geographic revenue breakdowns in the available data, so it is not possible to assess revenue concentration or geographic exposure. The company's business appears to be focused on a single therapeutic area, with no diversification across product lines or geographies. The company is in a growth phase, with a market price of $0.96 and a market cap of $26.85 million. Analysts have assigned a mean price target of $7.42 and a median price target of $6.50, suggesting a potential upside of over 600% from the current price. The company has a mean recommendation of 2.25, indicating a generally positive outlook from analysts, with 1 strong buy, 4 buy, and 3 hold ratings. Jasper Therapeutics faces low liquidity and dilution risk, with no immediate filing-based flags detected. The company has a low dilution potential, with basic and diluted shares outstanding being equal at 27.99 million. No recent events or filings have been identified that would suggest a change in the company's capital structure or business strategy.